OC 59 - Hemophilia - Novel Therapies I (anti-TFPI)

Moderator(s)

• 

  Maria Elisa Mancuso, MD, PhD (she/her/hers)

  Senior Consultant in Haematology
  Center for Thrombosis and Hemorrhagic Diseases
  IRCCS Humanitas Research Hospital
  Milan, Lombardia, Italy
• 

  Soumitra  Tole, MD MSc FRCPC (he/him/his)

  Pediatric Hematologist/Oncologist; Assistant Professor
  Children's Hospital, London Health Science Centre; Western University
  London, Ontario, Canada

Presentations:

• 14:45 – 15:00 ET

  Concizumab prophylaxis in patients with haemophilia A or B without inhibitors: Efficacy and safety results from the primary analysis of the phase 3 explorer8 study
  

  Presenting Author: Pratima Chowdary, MD – Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free London NHS Foundation Trust, London, United Kingdom

  Co-Author: Pantep Angchaisuksiri, MD – Division of Hematology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

  Co-Author: Shashikant Apte – Sahyadri Speciality Hospital, Pune, Maharashtra, India

  Co-Author: Anthony KC. Chan, MBBS – McMaster University, McMaster Children’s Hospital, Hamilton, Canada

  Co-Author: Sanja H. Jacobsen – Novo Nordisk A/S, Søborg, Denmark

  Co-Author: Victor Jiménez Yuste – Haematology Department, La Paz University Hospital, IdiPAZ, Universidad Autónoma Madrid, Madrid, Spain

  Co-Author: Jay Jay Thaung Zaw – Novo Nordisk A/S, Søborg, Denmark

  Co-Author: Allison P. Wheeler – Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA

  Co-Author: Jerzy Windyga, Prof. dr med. (he/him/his) – Institute of Hematology and Transfusion Medicine

  Co-Author: Hermann Eichler, MD (he/him/his) – Institute of Clinical Haemostaseology and Transfusion Medicine, University and University Hospital of the Saarland, Homburg, Germany
• 15:00 – 15:15 ET

  Analyzing Concizumab mechanism of action by a Mathematical Modeling Approach
  

  Co-Author: Kenji Miyazawa – Colorado School of Mines

  Co-Author: Alan E. Mast, MD, PhD (he/him/his) – Versiti

  Co-Author: Michael Dockal – Novo Nordisk

  Co-Author: Marianne Kjalke, PhD (she/her/hers) – Department of Rare Blood Disorders, Novo Nordisk A/S, Måløv, Denmark

  Presenting Author: Karin Leiderman, PhD (she/her/hers) – University of North Carolina at Chapel Hill
• 15:15 – 15:30 ET

  Pooled Safety Results from the Multidose explorer Studies of Concizumab in Patients with Haemophilia
  

  Presenting Author: Hermann Eichler, MD (he/him/his) – Institute of Clinical Haemostaseology and Transfusion Medicine, University and University Hospital of the Saarland, Homburg, Germany

  Co-Author: Tadashi Matsushita – Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan.

  Co-Author: Pantep Angchaisuksiri, MD – Division of Hematology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

  Co-Author: Giancarlo Castaman, MD – Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, Italy

  Co-Author: Galal Eliraqi – Novo Nordisk, Søborg, Denmark

  Co-Author: Kaan Kavakli – Department of Hematology, Ege University Children’s Hospital, Izmir, Turkey

  Co-Author: Michelle C. Ogden – Novo Nordisk, Søborg, Denmark

  Co-Author: Josephine S. Rasmussen – Novo Nordisk, Søborg, Denmark

  Co-Author: Allison P. Wheeler – Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA

  Co-Author: Amy Shapiro – Indiana Hemophilia & Thrombosis Center, Indianapolis, IN, USA

  Co-Author: Jan Astermark – Department of Hematology Oncology and Radiation Physics, Skane University Hospital, and Institution of Translational Medicine, Lund University, Malmö, Sweden
• 15:30 – 15:45 ET

  Health-related quality of life, treatment burden and patient preference in patients with haemophilia A/B without inhibitors on concizumab prophylaxis: results from the phase 3 explorer8 study
  

  Presenting Author: Guy Young, MD – Children's Hospital Los Angeles

  Co-Author: Gary M. Benson, BCh BAO FRCP FRCPath – Belfast Health and Social Care Trust

  Co-Author: Hermann Eichler, MD (he/him/his) – Institute of Clinical Haemostaseology and Transfusion Medicine, University and University Hospital of the Saarland, Homburg, Germany

  Co-Author: Johnny Mahlangu, MD (he/him/his) – Haemophilia Comprehensive Care Centre, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand and National Health Laboratory Service, Johannesburg, South Africa

  Co-Author: Jan Odgaard-Jensen – Novo Nordisk A/S, Søborg, Denmark

  Co-Author: Jesper S. Neergaard – Novo Nordisk A/S, Søborg, Denmark

  Co-Author: Jay Jay Thaung Zaw – Novo Nordisk A/S, Søborg, Denmark

  Co-Author: Jameela Sathar – Department of Hematology, Hospital Ampang, Ampang, Selangor, Malaysia

  Co-Author: Huyen Tran – Australian Centre for Blood Diseases, Monash University

  Co-Author: Tadashi Matsushita – Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan.
• 15:45 – 16:00 ET

  Evaluation of Concizumab in Hemophilia Using Microfluidic Flow Assays
  

  Presenting Author: Megan P. Jewell, PhD (she/her/hers) – University of Colorado Anschutz Medical Campus

  Co-Author: Adam Wufsus – Novo Nordisk

  Co-Author: Chiara Pallini – Novo Nordisk

  Co-Author: Michael Dockal – Novo Nordisk

  Co-Author: Marianne Kjalke, PhD (she/her/hers) – Department of Rare Blood Disorders, Novo Nordisk A/S, Måløv, Denmark

  Co-Author: Keith B. Neeves, PhD – University of Colorado Anschutz Medical Campus